Cart
×
Happy Holidays from PTC Therapeutics
We are sharing a holiday message and community update from PTC Therapeutics. Dear Duchenne Community, As we enter the holiday season, I wanted to thank the community for all your […]
Recap of PTC Therapeutics Community Conference Call Re: Ataluren
PTC Therapeutics held a community conference today regarding Ataluren. Stuart Peltz, President and CEO, PTC Therapeutics, Inc., welcomed and thanked the community as well as […]
CureDuchenne Launches Virtual Durable Medical Equipment Expo for the Duchenne Community
NEWPORT BEACH, Calif., October 26, 2017 – CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, launched the CureDuchenne Cares Virtual Durable Medical Equipment […]
PTC to File a Formal Dispute Resolution, Host Duchenne Community Call
Dear Duchenne Community, As you might have seen, the Office of Drug Evaluation I of the FDA provided a Complete Response Letter (CRL) for the application to market ataluren in […]
PTC Therapeutics Receives Complete Response Letter for Ataluren’s NDA
PTC Therapeutics received a Complete Response Letter from the Food and Drug Administration (FDA) for Ataluren’s New Drug Application (NDA). This means that the FDA has completed its review of […]
Letter to the Community from PTC Therapeutics
Dear Duchenne Community, On behalf of all of PTC, we want to thank all of you for supporting the advisory committee review of ataluren. As you know, the meeting was […]
PTC /Ataluren – FDA AdCom Meeting September 28, 2017
CureDuchenne is pleased to see that the FDA will hold an Advisory Committee Meeting (AdCom) for PTC Therapeutics’s drug Ataluren. We are hopeful for a full and fair review which […]
EMFLAZA Bridge Program and Prescription Start Form
PTC is committed to getting patients onto EMFLAZA as quickly as possible, without interruption of therapy. For patients that are currently accessing EMFLAZA through Master Pharmacy importation from outside of […]
EMFLAZA Launch Plan
Today, PTC Therapeutics hosted a call for the Duchenne community to announce pricing and services for their launch of EMFLAZA, the commercial name for deflazacort. The announced price will be […]